indomethacin has been researched along with Bacterial Disease in 22 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Excerpt | Relevance | Reference |
---|---|---|
"The effect of indomethacin (1 mg/kg) on gas exchange was studied in ten patients with hypoxaemic respiratory failure precipitated by bacterial pneumonia." | 7.67 | Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. ( Dobson, K; Hanly, PJ; Light, RB; Roberts, D, 1987) |
"The effect of indomethacin (1 mg/kg) on gas exchange was studied in ten patients with hypoxaemic respiratory failure precipitated by bacterial pneumonia." | 3.67 | Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. ( Dobson, K; Hanly, PJ; Light, RB; Roberts, D, 1987) |
"Pretreatment with indomethacin significantly decreased the proportion of fetal death from 83% to < 25% in mice injected with 10 micrograms of LPS." | 1.29 | Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. ( Branch, DW; Dudley, DJ; Edwin, SS; Mitchell, MD; Silver, RM; Simmons, DL; Trautman, MS, 1995) |
"Indomethacin sodium promotes closure of the patent ductus arteriosus in premature infants." | 1.27 | Indomethacin-associated sepsis in very-low-birth-weight infants. ( Eisenfeld, LI; Herson, VC; Krause, PJ; Maderazo, EG; Pontius, L, 1988) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 12 (54.55) | 18.7374 |
1990's | 6 (27.27) | 18.2507 |
2000's | 2 (9.09) | 29.6817 |
2010's | 2 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Shelke, SH | 1 |
Mhaske, PC | 1 |
Nandave, M | 1 |
Narkhade, S | 1 |
Walhekar, NM | 1 |
Bobade, VD | 1 |
McElroy, SJ | 1 |
Gordon, PV | 1 |
Attridge, JT | 1 |
Porras, M | 1 |
MartÃn, MT | 1 |
Soler, M | 1 |
Vergara, P | 1 |
Burke, V | 1 |
Gracey, M | 1 |
Korman, SH | 1 |
Berant, M | 1 |
Alon, U | 1 |
Horan, TD | 1 |
English, D | 1 |
McPherson, TA | 1 |
Friedman, CA | 1 |
Parks, BR | 1 |
Rawson, JE | 1 |
Serwer, GA | 1 |
Anderson, PA | 1 |
Meyer, TA | 1 |
Wang, J | 1 |
Tiao, GM | 1 |
Ogle, CK | 2 |
Fischer, JE | 3 |
Hasselgren, PO | 3 |
Silver, RM | 1 |
Edwin, SS | 1 |
Trautman, MS | 1 |
Simmons, DL | 1 |
Branch, DW | 1 |
Dudley, DJ | 1 |
Mitchell, MD | 1 |
Ohno, Y | 1 |
Kasugai, M | 1 |
Kurauchi, O | 1 |
Mizutani, S | 1 |
Tomoda, Y | 1 |
West, MA | 1 |
Manthei, R | 1 |
Bubrick, MP | 1 |
Newton, ER | 1 |
Shields, L | 1 |
Ridgway, LE | 1 |
Berkus, MD | 1 |
Elliott, BD | 1 |
Horgan, PG | 1 |
Mannick, JA | 1 |
Dubravec, DB | 1 |
Rodrick, ML | 1 |
Nakai, S | 1 |
Hirai, Y | 1 |
Kramarev, SA | 1 |
Hanly, PJ | 1 |
Roberts, D | 1 |
Dobson, K | 1 |
Light, RB | 1 |
Bihari, DJ | 1 |
Salzer, HR | 1 |
Salzer-Muhar, U | 1 |
Pollak, A | 1 |
Weninger, M | 1 |
Warner, BW | 2 |
Hummel, RP | 2 |
James, JH | 2 |
Herson, VC | 1 |
Krause, PJ | 1 |
Eisenfeld, LI | 1 |
Pontius, L | 1 |
Maderazo, EG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 189 |
Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1078 |
Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 78 |
Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 303 |
Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 134 |
Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 141 |
Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 42 |
Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 352 |
Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 264 |
Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 668 |
Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1506 |
Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 214 |
Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 26 |
Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 54 |
Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 9 |
Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 23 |
Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 290 |
Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 8 |
Placebo Arm | 21 |
2 reviews available for indomethacin and Bacterial Disease
Article | Year |
---|---|
Understanding clinical literature relevant to spontaneous intestinal perforations.
Topics: Acute Disease; Bacterial Infections; Critical Care; Dexamethasone; Drug Therapy, Combination; Female | 2009 |
Review: prostaglandins in diarrheal states.
Topics: Aspirin; Bacterial Infections; Child; Cholera Toxin; Colonic Diseases; Cyclic AMP; Diarrhea; Dinopro | 1981 |
1 trial available for indomethacin and Bacterial Disease
Article | Year |
---|---|
Combination antibiotics and indomethacin in idiopathic preterm labor: a randomized double-blind clinical trial.
Topics: Ampicillin; Bacterial Infections; Double-Blind Method; Drug Therapy, Combination; Female; Humans; In | 1991 |
19 other studies available for indomethacin and Bacterial Disease
Article | Year |
---|---|
Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Bacteria; Bacterial Infections; Carrageena | 2012 |
Unraveling the enigma that is neonatal necrotizing enterocolitis.
Topics: Bacterial Infections; Dexamethasone; Female; Humans; Indomethacin; Infant, Very Low Birth Weight; In | 2014 |
Intestinal motor disorders associated with cyclical bacterial overgrowth in a rat model of enteritis.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacteria; Bacterial Infections; Bac | 2004 |
Studies with enterotoxigenic microorganisms: effects of candidate antidiarrhoeals in experimental animals in vivo.
Topics: Aluminum Hydroxide; Animals; Antidiarrheals; Aspirin; Bacterial Infections; Charcoal; Chlorpromazine | 1984 |
Association of neutrophil chemiluminescence with microbicidal activity.
Topics: 4-Chloromercuribenzenesulfonate; Ascorbic Acid; Bacterial Infections; Blood Bactericidal Activity; C | 1982 |
Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure.
Topics: Bacterial Infections; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Half-Life; Humans | 1982 |
Sepsis and endotoxemia stimulate intestinal interleukin-6 production.
Topics: Animals; Bacterial Infections; Base Sequence; Dinoprostone; Endotoxins; Indomethacin; Interleukin-6; | 1995 |
Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide.
Topics: Abortion, Spontaneous; Animals; Bacterial Infections; Decidua; Dose-Response Relationship, Drug; Enz | 1995 |
Effect of interleukin 2 on the production of progesterone and prostaglandin E2 in human fetal membranes and its consequences for preterm uterine contractions.
Topics: Amniotic Fluid; Bacterial Infections; Chorioamnionitis; Culture Techniques; Dinoprostone; Extraembry | 1994 |
Autoregulation of hepatic macrophage activation in sepsis.
Topics: Bacterial Infections; Cells, Cultured; Dinoprostone; Dose-Response Relationship, Drug; Homeostasis; | 1993 |
Effect of low dose recombinant interleukin 2 plus indomethacin on mortality after sepsis in a murine burn model.
Topics: Animals; Bacterial Infections; Burns; Disease Models, Animal; Drug Therapy, Combination; Indomethaci | 1990 |
The therapeutic potential of interleukin-1 beta in the treatment of chemotherapy- or radiation-induced myelosuppression and in tumor therapy.
Topics: Animals; Antineoplastic Agents; Bacterial Infections; Bone Marrow; Combined Modality Therapy; Diseas | 1989 |
[The use of indomethacin in acute intestinal infections].
Topics: Acute Disease; Bacterial Infections; Child, Preschool; Convalescence; Dinoprost; Drug Evaluation; Hu | 1989 |
Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Critical Care; Humans; Hypoxia; | 1987 |
Indomethacin and arterial oxygenation in critically ill patients with severe bacterial pneumonia.
Topics: Arteries; Bacterial Infections; Critical Care; Humans; Indomethacin; Lung; Microcirculation; Oxygen; | 1987 |
Sepsis and indomethacin failure in premature infants with symptomatic patent ductus arteriosus.
Topics: Bacterial Infections; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prem | 1987 |
Further evidence that accelerated muscle protein breakdown during sepsis is not mediated by prostaglandin E2.
Topics: Animals; Bacterial Infections; Dinoprostone; Indomethacin; Male; Muscle Proteins; Muscles; Prostagla | 1988 |
Indomethacin-associated sepsis in very-low-birth-weight infants.
Topics: Bacterial Infections; Blood Bactericidal Activity; Cell Movement; Chemotaxis, Leukocyte; Ductus Arte | 1988 |
Effects of indomethacin and leupeptin on muscle cathepsin B activity and protein degradation during sepsis.
Topics: Animals; Bacterial Infections; Cathepsin B; Indomethacin; Leupeptins; Muscle Proteins; Muscles; Olig | 1988 |